Skip to main
IMRX

Immuneering Corp (IMRX) Stock Forecast & Price Target

Immuneering Corp (IMRX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immuneering Corp's progress in its clinical trials highlights significant advancements in overall survival (OS) and progression-free survival (PFS) rates, demonstrating marked improvements over existing standard of care (SoC) treatments for oncologic diseases. The improved safety profile of atebimetinib, along with its favorable tolerability compared to current therapies, strengthens its positioning in the market and enhances its potential to attract partnerships with pharmaceutical and biotechnology companies. Additionally, compelling case studies showcasing remarkable patient responses further bolster the outlook for the company's drug discovery programs and overall growth potential.

Bears say

The analysis highlights multiple regulatory risks associated with Immuneering Corp's product development that could lead to downward revisions in financial projections. The potential need for additional capital raises before achieving profitability raises concerns about share dilution for current shareholders. Furthermore, the ability of IMM-1-104 to significantly differentiate from existing MEKi profiles regarding activity or tolerability remains uncertain, which could further adversely impact financial estimates.

Immuneering Corp (IMRX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immuneering Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immuneering Corp (IMRX) Forecast

Analysts have given Immuneering Corp (IMRX) a Buy based on their latest research and market trends.

According to 6 analysts, Immuneering Corp (IMRX) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immuneering Corp (IMRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.